Aethlon Medical Inc. (AEMD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 2, 2025, reports on material definitive agreements entered into by Aethlon Medical, Inc. on December 5, 2025. The Company, a Nevada corporation headquartered in San Diego, California, is engaged in a capital raise to support its operations.
Key Financial Metrics and Capital Structure
The filing details a Private Investment in Public Equity (PIPE) offering and a Warrant Inducement Agreement. Key financial terms include:
- Gross Proceeds: Estimated at approximately $3.3 million from the combined PIPE Offering and Warrant Inducement.
- PIPE Offering: Issuance of 596,452 shares of Common Stock (or pre-funded warrants) and 1,043,791 Common Warrants.
- Offering Price: $4.03 per share for the Shares and accompanying Common Warrants.
- Warrant Inducement: Reduction of exercise price on existing warrants to $4.03 per share and issuance of new warrants for 175% of the shares issued upon exercise of existing warrants.
- Transaction Costs: Placement agent fees of 6.5% of gross proceeds for both the PIPE and Warrant Inducement, plus up to $50,000 in expense reimbursements and a 4% warrant to the placement agent.
- Use of Proceeds: Working capital and general corporate purposes.
The filing does not provide specific data on current revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement and a Warrant Inducement Agreement. Key provisions include:
- Closing Date: Expected on December 8, 2025, subject to customary conditions.
- Lock-Up Provisions: The Company is restricted from issuing new equity or entering variable rate transactions for 30 days to six months following shareholder approval and registration effectiveness.
- Registration Rights: The Company must file a registration statement for the resale of shares within 30 days (PIPE) or 90 days (Warrant Inducement) of the agreement date.
- Warrant Terms: New warrants have an exercise price of $4.03, are exercisable after shareholder approval, and expire 5.5 years from the Shareholder Approval Date. They include cashless exercise options if a registration statement is not effective.
Outlook, Risks, and Contingencies
Management intends to use the net proceeds for working capital. The transaction is contingent upon shareholder approval for the issuance of shares underlying the warrants. Risks and contingencies identified include:
- Shareholder Approval: The exercisability of the new warrants is dependent on stockholder approval. If not obtained at the first meeting, the proposal must be included in the next two annual meetings.
- Liquidated Damages: The Company faces potential liquidated damages if the resale registration statement for the new warrants is not filed within 90 days.
- Dilution: The issuance of shares and warrants, including the 175% bonus in the warrant inducement, will result in significant dilution to existing shareholders.
- Market Conditions: The offering is priced at $4.03, reflecting the closing price on December 4, 2025.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received versus the estimated $3.3 million.
- Confirm the outcome of the shareholder vote required to make the new warrants exercisable.
- Review the full text of the Securities Purchase Agreement and Warrant Inducement Agreement (Exhibits 10.1 and 10.3) for specific anti-dilution adjustments and penalty clauses.
- Monitor the filing and effectiveness of the resale registration statements required within 30 and 90 days.
- Assess the impact of the 6.5% placement fees and 4% agent warrant on the net capital raised.